FDA approves Zepzelca (lurbinectedin) for treatment of advanced SCLC that has progressed after platinum chemotherapy

[Miranda_GO2]

On June 15, 2020, the Food and Drug Administration (FDA) approved Zepzelca (lurbinectedin) for treatment of advanced small cell lung cancer (SCLC) whose cancer has progressed after platinum chemotherapy. The FDA based their approval on the results of a clinical trial which showed that a high percentage of patients receiving Zepzelca experienced a response to the treatment. In addition, the response lasted for a significant amount of time.

Zepzelca marks a new option for patients living with SCLC that they did not have before. This new option gives patients hope of alternative treatments in a field where there have been few effective therapies.

Here's the link to read the full press release: fda.gov/drugs/drug-approval...

Please feel free to reach out to [e-mail] if you have any questions about this approval or any others.

[Denzie Moderator Volunteer]

This is wonderful! There are so few alternatives for SCLC.